Cross-talk between Myc and p53 in B-cell lymphomas

Myc and p53 proteins are closely associated with many physiological cellular functions, including immune response and lymphocyte survival, and are expressed in the lymphoid organs, which are sites for the development and activation of B-cell malignancies. Genetic alterations and other mechanisms res...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Yu, Tian-Tian Yu, Ken H. Young
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2e50e4d5d0694a7cb39a7af56ef27f59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e50e4d5d0694a7cb39a7af56ef27f59
record_format	dspace
spelling	oai:doaj.org-article:2e50e4d5d0694a7cb39a7af56ef27f592021-12-02T11:52:55ZCross-talk between Myc and p53 in B-cell lymphomas2095-882X10.1016/j.cdtm.2019.08.001https://doaj.org/article/2e50e4d5d0694a7cb39a7af56ef27f592019-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X19300660https://doaj.org/toc/2095-882XMyc and p53 proteins are closely associated with many physiological cellular functions, including immune response and lymphocyte survival, and are expressed in the lymphoid organs, which are sites for the development and activation of B-cell malignancies. Genetic alterations and other mechanisms resulting in constitutive activation, rearrangement, or mutation of MYC and TP53 contribute to the development of lymphomas, progression and therapy resistance by gene dysregulation, activation of downstream anti-apoptotic pathways, and unfavorable microenvironment interactions. The cross-talk between the Myc and p53 proteins contributes to the inferior prognosis in many types of B-cell lymphomas. In this review, we present the physiological roles of Myc and p53 proteins, and recent advances in understanding the pathological roles of Myc, p53, and their cross-talk in lymphoid neoplasms. In addition, we highlight clinical trials of novel agents that directly or indirectly inhibit Myc and/or p53 protein functions and their signaling pathways. Although, to date, these trials have failed to overcome drug resistance, the new results have highlighted the clinical efficiency of targeting diverse mechanisms of action with the goal of optimizing novel therapeutic opportunities to eradicate lymphoma cells. Keywords: B-cell lymphoma, p53, Myc, Molecular mechanisms, Targeted therapyLi YuTian-Tian YuKen H. YoungKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 3, Pp 139-154 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Li Yu Tian-Tian Yu Ken H. Young Cross-talk between Myc and p53 in B-cell lymphomas
description	Myc and p53 proteins are closely associated with many physiological cellular functions, including immune response and lymphocyte survival, and are expressed in the lymphoid organs, which are sites for the development and activation of B-cell malignancies. Genetic alterations and other mechanisms resulting in constitutive activation, rearrangement, or mutation of MYC and TP53 contribute to the development of lymphomas, progression and therapy resistance by gene dysregulation, activation of downstream anti-apoptotic pathways, and unfavorable microenvironment interactions. The cross-talk between the Myc and p53 proteins contributes to the inferior prognosis in many types of B-cell lymphomas. In this review, we present the physiological roles of Myc and p53 proteins, and recent advances in understanding the pathological roles of Myc, p53, and their cross-talk in lymphoid neoplasms. In addition, we highlight clinical trials of novel agents that directly or indirectly inhibit Myc and/or p53 protein functions and their signaling pathways. Although, to date, these trials have failed to overcome drug resistance, the new results have highlighted the clinical efficiency of targeting diverse mechanisms of action with the goal of optimizing novel therapeutic opportunities to eradicate lymphoma cells. Keywords: B-cell lymphoma, p53, Myc, Molecular mechanisms, Targeted therapy
format	article
author	Li Yu Tian-Tian Yu Ken H. Young
author_facet	Li Yu Tian-Tian Yu Ken H. Young
author_sort	Li Yu
title	Cross-talk between Myc and p53 in B-cell lymphomas
title_short	Cross-talk between Myc and p53 in B-cell lymphomas
title_full	Cross-talk between Myc and p53 in B-cell lymphomas
title_fullStr	Cross-talk between Myc and p53 in B-cell lymphomas
title_full_unstemmed	Cross-talk between Myc and p53 in B-cell lymphomas
title_sort	cross-talk between myc and p53 in b-cell lymphomas
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/2e50e4d5d0694a7cb39a7af56ef27f59
work_keys_str_mv	AT liyu crosstalkbetweenmycandp53inbcelllymphomas AT tiantianyu crosstalkbetweenmycandp53inbcelllymphomas AT kenhyoung crosstalkbetweenmycandp53inbcelllymphomas
_version_	1718394915304505344

Cross-talk between Myc and p53 in B-cell lymphomas

Ejemplares similares